Compare
Serina Therapeutics, Inc. vs iBio, Inc. vs Lisata Therapeutics, Inc. vs Actinium Pharmaceuticals, Inc.
| Latest fiscal year | Serina Therapeutics, Inc. SER | iBio, Inc. IBIO | Lisata Therapeutics, Inc. LSTA | Actinium Pharmaceuticals, Inc. ATNM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $130.0K | $100.0K | $170.0K | $90.0K |
| Revenue growth (YoY) | +132.1% | -75.0% | -83.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$19.18M | -$33.04M | -$16.59M | -$33.89M |
| EPS (Diluted) | -$1.91 | -$0.32 | -$1.91 | -$1.09 |
| Operating cash flow | -$17.95M | -$23.22M | -$15.95M | -$24.58M |
| Free cash flow | -$18.01M | -$23.80M | -$15.98M | -$24.68M |
| Cash & equivalents | $3.06M | $56.40M | $15.96M | $48.00M |
| Total assets | $6.95M | $99.11M | $17.74M | $51.77M |
| Total liabilities | $6.99M | $13.40M | $3.14M | $43.94M |
| Shareholders' equity | -$37.0K | $85.71M | $14.86M | $7.83M |
| Return on year-end equity | n/a | -38.6% | -111.7% | -432.6% |
| Shares outstanding | 10.77M | 55.70M | 8.83M | 31.20M |
Revenue, most recent five fiscal years
| Fiscal year | Serina Therapeutics, Inc. | iBio, Inc. | Lisata Therapeutics, Inc. | Actinium Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $130.0K Ended 2025-12-31 | $100.0K Ended 2026-06-30 | $170.0K Ended 2025-12-31 | $90.0K Ended 2025-12-31 |
| 1 year earlier | $56.0K Ended 2024-12-31 | $400.0K Ended 2025-06-30 | $1.00M Ended 2024-12-31 | n/a |
| 2 years earlier | $3.15M Ended 2023-12-31 | $225.0K Ended 2024-06-30 | $0 Ended 2023-12-31 | $81.0K Ended 2023-12-31 |
| 3 years earlier | $34.0K Ended 2022-12-31 | $0 Ended 2023-06-30 | $0 Ended 2022-12-31 | $1.03M Ended 2022-12-31 |
| 4 years earlier | $144.0K Ended 2021-12-31 | $1.88M Ended 2022-06-30 | n/a | $1.14M Ended 2021-12-31 |